Funding for this research was provided by:
Cancer Research UK (C423/A1421, C309/A11566, C423/A15043, C368/A6743, A368/A7990)
World Cancer Research Fund (12-1280)
Wellcome Trust (094885/Z/10/Z)
Received: 16 February 2019
Revised: 7 May 2019
Accepted: 13 May 2019
First Online: 12 July 2019
Change Date: 24 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Compliance with ethical standards
: CZ, BA-L, SE, ADHB, FR, AH, PAC and PW are current employees of The Institute of Cancer Research, which has a Rewards to Inventors scheme and has a commercial interest in the development of inhibitors of CDKs, with intellectual property licensed to, and research funding provided by Merck and Cyclacel Pharmaceuticals. PW is a consultant for Astex Pharmaceuticals, CV6 Therapeutics, Nextechinvest and Storm Therapeutics and holds equity in Nextechinvest, Storm Therapeutics and Chroma Therapeutics. BAL consults for or is a member of the advisory board for GSK and Astex Pharmaceuticals, and she is a former employee of Inpharmatica Ltd. All other authors declare that there is no conflict of interest regarding the content and publication of this article.